Investmark Advisory Group’s GT Biopharma GTBP Stock Holding History

Investmark Advisory Group’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-48	Closed	-$4K	–	205
2021 Q4	$4K	Buy	+48	New	+$7.18K	﹤0.01%	328

Other funds holding GTBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Investmark Advisory Group's GTBP Position: Q1 2022 in Review

Investmark Advisory Group sold out of GT Biopharma (GTBP) in Q1 2022, closing a stake of 48 shares — an estimated $4K sold.

Investmark Advisory Group first reported a position in GTBP in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 57 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

Investmark Advisory Group reported no remaining GT Biopharma position as of Q1 2022 after selling out during the quarter.
Investmark Advisory Group sold 48 GT Biopharma shares in Q1 2022, an estimated $4K.
Investmark Advisory Group first reported a position in GT Biopharma in Q4 2021 and held it in 1 quarter.
Investmark Advisory Group's GT Biopharma position peaked at $4K in Q4 2021.
57 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on Investmark Advisory Group's 13F filing for Q1 2022, filed 3 May 2022.